DOI: https://dx.doi.org/10.18565/pharmateca.2022.13.106-109
Верещагин Е.И., Свечникова Е.В., Артемьева Н.О.
1) Новосибирский государственный медицинский университет, Новосибирск, Россия; 2) Поликлиника № 1 УДП РФ, Москва, Россия; 3) Клиника превентивной и эстетической медицины «Body Project», Москва, Россия
1. Emmerson B.T. Effect of oral fructose on urate production. Ann Rheum Dis. 1974;33:276–80. 2. Fathallah-Shaykh S.A. Cramer MT Uric acid and the kidney Pediatr Nephrol. 2014;29(6):999– 1008. Doi: 10.1007/s00467-013-2549-x. 3. King C., Lanaspa M.A., Jensen T., Tolan D.R., Sбnchez-Lozada L.G. Johnson RJUric Acid as a Cause of the Metabolic Syndrome. Contrib Nephrol. 2018;192:88–102. Doi: 10.1159/000484283. 4. Young H.R., Yanyan Z., Hyon KCThe epidemiology of uric acid and fructose Semin Nephrol. 2011;31(5):410–19. Doi: 10.1016/j.semnephrol.2011.08.004. 5. Pergola G., Cortese F., Termine G., et al. Uric Acid, Metabolic Syndrome and Atherosclerosis: The Chicken or the Egg, Which Comes First? Endocr Metab Immune Disord Drug Targets. 2018;18(3):251–59. Doi: 10.2174/1871530318666180212101548. 6. Abdullah A.R., Hasan H.A., Raigangar V.L. Analysis of the relationship of leptin, high-sensitivity C-reactive protein, adiponectin, insulin, and uric acid to metabolic syndrome in lean, overweight, and obese young females. Metab Syndr Relat Disord. 2009;7(1):17–22. Doi: 10.1089/ met.2008.0045. 7. Choi H.K., Ford E.S. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med. 2007;120:442–47. 8. Johnson R.J., Nakagawa T., Sanchez-Lozada L.G., et al. Sugar, Uric Acid, and the Etiology of Diabetes and Obesity. Diabetes. 2013;62(10): 3307–15. 9. Bonakdaran S., Kharaqani B. Association of serum uric acid and metabolic syndrome in type 2 diabetes Curr Diabetes Rev. 2014;10(2):113– 17. Doi: 10.2174/15733998106661402281 60938. 10. Lanaspa M.A., Sanchez-Lozada L.G., Choi Y.J., et al. Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and -independent fatty liver. J Biol Chem. 2012;287:40732–44. 11. Rho Y.H., Zhu Y., Choi H.K. The epidemiology of uric acid and fructose. Semin Nephrol. 2011 Sep;31(5):410–19. Doi: 10.1016/j. semnephrol.2011.08.004). 12. Luk A.J., Levin G.P., Moore E.E., et al. Allopurinol and mortality in hyperuricaemic patientsRheumatology. 2009; 48(7):804–6. Doi: 10.1093/rheumatology/kep069. 13. Ogino K., Kato M., Furuse Y. Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study. Circ Heart Fail. 2010;3:73–81. 14. Lee M.H., Graham G.G., Williams K.M., Day R.O. A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients? Drug Saf. 2008;31(8):643–65. Doi: 10.2165/00002018- 200831080-00002. 15. Havlik J., de la Huebra R.G., Hejtmankova K., et al. Xanthine oxidase inhibitory properties of Czech medicinal plants J Ethnopharmacol. 2010;132(2):461–65. Doi: 10.1016/j. jep.2010.08.044. 16. Gainche M., Ogeron C., Ripoche I., et al. Xanthine Oxidase Inhibitors from Filipendula ulmaria (L.) Maxim. and Their Efficient Detections by HPTLC and HPLC Analyses. 2021;26(7): 1939. 17. Crone C., Lassen U.V. Mechanism of increased renal urate excretion during administration of salicylic acid. Acta Pharmacol Toxicol. 1955;11(4):362–366. doi: 10.1111/j.1600– 0773.1955.tb03271.x.PMID: 13301786) 7. 18. Oliviero F., Scanu A., Zamudio-Cuevas Y., et al. Anti-inflammatory effects of polyphenols in arthritis J Sci Food Agric. 2018;98(5):1653–59. Doi: 10.1002/jsfa.8664. 19. Shi Y., Williamson G Quercetin lowers plasma uric acid in pre-hyperuricaemic males: a randomised, double-blinded, placebo-controlled, cross-over trial Br J Nutr. 2016;115(5):800-6. Doi: 10.1017/S0007114515005310. 20. Chen Y., Zhao Z., Li Y., et al. Baicalein alleviates hyperuricemia by promoting uric acid excretion and inhibiting xanthine oxidase. J Phytomedicine. 2021;80:153374. Doi: 10.1016/j. phymed.2020.153374.
Автор для связи: Евгений Иванович Верещагин, врач высшей категории, д.м.н, профессор, заведующий кафедрой анестезиологии и реаниматологии им. профессора И.П. Верещагина, Новосибирский государственный медицинский университет, Новосибирск, Россия; eivv1961@gmail.com ORCID:
Свечникова Е.В. (Svechnikova E.V.), https://orcid.org/0000-0002-5885-4872
Артемьева Н.О. (Artemyeva N.O.), https://orcid.org/0000-0002-5619-6757